Parathyroid Hormone Kinetics During CRRT
Study Details
Study Description
Brief Summary
The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation continuous renal replacement therapy.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Study group Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. |
Diagnostic Test: parathyroid hormone
10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
|
Outcome Measures
Primary Outcome Measures
- The change in parathyroid hormone serum concentration during regional citrate anticoagulation continuous renal replacement therapy (CRRT) in the acute phase of critical illness. [96 hours]
The first parathyroid hormone serum level will be measured before the start of CRRT (the zero point) Next measurements will be performed every 12 hours. Minimal number of measurements - 6, maximal - 8 per patient.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Acute respiratory failure
-
Acute circulatory failure
-
acute kidney injury treated with regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF
-
continuous renal replacement therapy started no later than 48 hours after admission
-
SOFA score 5 or more
Exclusion Criteria:
-
age less than 18 years
-
acute liver failure
-
hypercalcemia at admission (total calcium plasma level > 10.6 mg/dL; total ionized calcium plasma level > 1.35 mmol/L
-
parathyroid glands disease
-
end stage renal disease
-
therapeutic plasma exchange
-
extracorporeal membrane oxygenation
-
unfavorable outcome (death) predicted within 72 hours (as assessed by investigator)
-
lack of relatives consent
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Poland. | Wrocław | Lower Silesia | Poland | 50-367 |
2 | Department of Endocrinology, Szpital Wojewodzki w Opolu | Opole | Silesia | Poland | 45-372 |
3 | Department of Anesthesiology and Intensive Care, Uniwersytecki Szpital Kliniczny w Opolu | Opole | Silesia | Poland | 45-401 |
Sponsors and Collaborators
- Uniwersytecki Szpital Kliniczny w Opolu
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AKIparathormoneCRRTstudy